An Open‐Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC‐A12) as a First‐Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer